vs

Side-by-side financial comparison of Edwards Lifesciences (EW) and UGI CORP (UGI). Click either name above to swap in a different company.

UGI CORP is the larger business by last-quarter revenue ($2.1B vs $1.6B, roughly 1.3× Edwards Lifesciences). Edwards Lifesciences runs the higher net margin — 23.1% vs 14.4%, a 8.7% gap on every dollar of revenue. On growth, Edwards Lifesciences posted the faster year-over-year revenue change (16.7% vs 3.9%). Over the past eight quarters, Edwards Lifesciences's revenue compounded faster (9.7% CAGR vs -7.5%).

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.

UGI Corporation is a natural gas and electric power distribution company headquartered in King of Prussia, Pennsylvania, with extensive operations in the United States and Europe.

EW vs UGI — Head-to-Head

Bigger by revenue
UGI
UGI
1.3× larger
UGI
$2.1B
$1.6B
EW
Growing faster (revenue YoY)
EW
EW
+12.8% gap
EW
16.7%
3.9%
UGI
Higher net margin
EW
EW
8.7% more per $
EW
23.1%
14.4%
UGI
Faster 2-yr revenue CAGR
EW
EW
Annualised
EW
9.7%
-7.5%
UGI

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
EW
EW
UGI
UGI
Revenue
$1.6B
$2.1B
Net Profit
$380.7M
$297.0M
Gross Margin
78.0%
Operating Margin
1.8%
22.0%
Net Margin
23.1%
14.4%
Revenue YoY
16.7%
3.9%
Net Profit YoY
6.8%
-20.8%
EPS (diluted)
$0.66
$1.34

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EW
EW
UGI
UGI
Q1 26
$1.6B
Q4 25
$1.6B
$2.1B
Q3 25
$1.6B
$1.2B
Q2 25
$1.5B
$1.4B
Q1 25
$1.4B
$2.6B
Q4 24
$1.4B
$2.0B
Q3 24
$1.4B
$1.2B
Q2 24
$1.4B
$1.4B
Net Profit
EW
EW
UGI
UGI
Q1 26
$380.7M
Q4 25
$91.2M
$297.0M
Q3 25
$291.1M
$-13.0M
Q2 25
$333.2M
$-163.0M
Q1 25
$358.0M
$479.0M
Q4 24
$385.6M
$375.0M
Q3 24
$3.1B
$-273.0M
Q2 24
$366.3M
$-48.0M
Gross Margin
EW
EW
UGI
UGI
Q1 26
78.0%
Q4 25
78.1%
Q3 25
77.8%
Q2 25
77.5%
Q1 25
78.7%
Q4 24
78.9%
Q3 24
80.6%
Q2 24
79.9%
Operating Margin
EW
EW
UGI
UGI
Q1 26
1.8%
Q4 25
9.6%
22.0%
Q3 25
19.8%
1.1%
Q2 25
26.8%
-6.8%
Q1 25
27.9%
26.6%
Q4 24
22.6%
24.5%
Q3 24
25.9%
-20.4%
Q2 24
26.8%
5.0%
Net Margin
EW
EW
UGI
UGI
Q1 26
23.1%
Q4 25
5.8%
14.4%
Q3 25
18.7%
-1.1%
Q2 25
21.7%
-12.0%
Q1 25
25.3%
18.2%
Q4 24
27.8%
18.9%
Q3 24
226.7%
-22.6%
Q2 24
26.7%
-3.6%
EPS (diluted)
EW
EW
UGI
UGI
Q1 26
$0.66
Q4 25
$0.16
$1.34
Q3 25
$0.50
$-0.08
Q2 25
$0.56
$-0.76
Q1 25
$0.61
$2.19
Q4 24
$0.65
$1.74
Q3 24
$5.13
$-1.26
Q2 24
$0.61
$-0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EW
EW
UGI
UGI
Cash + ST InvestmentsLiquidity on hand
$251.0M
Total DebtLower is stronger
$6.0B
Stockholders' EquityBook value
$5.0B
Total Assets
$15.8B
Debt / EquityLower = less leverage
1.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EW
EW
UGI
UGI
Q1 26
Q4 25
$4.2B
$251.0M
Q3 25
$3.8B
$335.0M
Q2 25
$4.1B
$350.0M
Q1 25
$3.9B
$426.0M
Q4 24
$4.0B
$240.0M
Q3 24
$4.4B
$213.0M
Q2 24
$2.0B
$183.0M
Total Debt
EW
EW
UGI
UGI
Q1 26
Q4 25
$6.0B
Q3 25
$6.5B
Q2 25
$5.7B
Q1 25
$6.6B
Q4 24
$6.6B
Q3 24
$6.4B
Q2 24
$6.3B
Stockholders' Equity
EW
EW
UGI
UGI
Q1 26
Q4 25
$10.3B
$5.0B
Q3 25
$10.2B
$4.8B
Q2 25
$10.5B
$4.9B
Q1 25
$10.1B
$5.0B
Q4 24
$10.0B
$4.6B
Q3 24
$9.5B
$4.3B
Q2 24
$7.4B
$4.7B
Total Assets
EW
EW
UGI
UGI
Q1 26
Q4 25
$13.7B
$15.8B
Q3 25
$13.3B
$15.5B
Q2 25
$13.5B
$15.4B
Q1 25
$13.0B
$15.7B
Q4 24
$13.1B
$15.4B
Q3 24
$13.0B
$15.1B
Q2 24
$10.1B
$15.1B
Debt / Equity
EW
EW
UGI
UGI
Q1 26
Q4 25
1.19×
Q3 25
1.37×
Q2 25
1.17×
Q1 25
1.32×
Q4 24
1.44×
Q3 24
1.48×
Q2 24
1.34×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EW
EW
UGI
UGI
Operating Cash FlowLast quarter
$66.0M
Free Cash FlowOCF − Capex
$-155.0M
FCF MarginFCF / Revenue
-7.5%
Capex IntensityCapex / Revenue
10.7%
Cash ConversionOCF / Net Profit
0.22×
TTM Free Cash FlowTrailing 4 quarters
$282.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EW
EW
UGI
UGI
Q1 26
Q4 25
$450.9M
$66.0M
Q3 25
$573.7M
$90.0M
Q2 25
$290.2M
$289.0M
Q1 25
$280.4M
$684.0M
Q4 24
$-127.5M
$164.0M
Q3 24
$351.8M
$151.0M
Q2 24
$371.5M
$390.0M
Free Cash Flow
EW
EW
UGI
UGI
Q1 26
Q4 25
$353.5M
$-155.0M
Q3 25
$516.2M
$-168.0M
Q2 25
$240.9M
$67.0M
Q1 25
$224.4M
$538.0M
Q4 24
$-177.3M
$-47.0M
Q3 24
$299.9M
$-115.0M
Q2 24
$286.1M
$185.0M
FCF Margin
EW
EW
UGI
UGI
Q1 26
Q4 25
22.5%
-7.5%
Q3 25
33.2%
-14.4%
Q2 25
15.7%
4.9%
Q1 25
15.9%
20.4%
Q4 24
-12.8%
-2.4%
Q3 24
22.1%
-9.5%
Q2 24
20.9%
13.7%
Capex Intensity
EW
EW
UGI
UGI
Q1 26
Q4 25
6.2%
10.7%
Q3 25
3.7%
22.1%
Q2 25
3.2%
16.3%
Q1 25
4.0%
5.5%
Q4 24
3.6%
10.6%
Q3 24
3.8%
22.0%
Q2 24
6.2%
15.2%
Cash Conversion
EW
EW
UGI
UGI
Q1 26
Q4 25
4.94×
0.22×
Q3 25
1.97×
Q2 25
0.87×
Q1 25
0.78×
1.43×
Q4 24
-0.33×
0.44×
Q3 24
0.11×
Q2 24
1.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons